Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CervoMed Inc. (CRVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: CRVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.83
1 Year Target Price $15.83
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 126.81% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.17M USD | Price to earnings Ratio - | 1Y Target Price 15.83 |
Price to earnings Ratio - | 1Y Target Price 15.83 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.80 - 20.63 | Updated Date 07/5/2025 |
52 Weeks Range 1.80 - 20.63 | Updated Date 07/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.17 |
Earnings Date
Report Date 2025-06-13 | When After Market | Estimate -0.6233 | Actual -0.56 |
Profitability
Profit Margin -200.58% | Operating Margin (TTM) -276.55% |
Management Effectiveness
Return on Assets (TTM) -56.19% | Return on Equity (TTM) -93.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13925848 | Price to Sales(TTM) 5.28 |
Enterprise Value 13925848 | Price to Sales(TTM) 5.28 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.64 | Shares Outstanding 8702720 | Shares Floating 4930090 |
Shares Outstanding 8702720 | Shares Floating 4930090 | ||
Percent Insiders 33.38 | Percent Institutions 26.31 |
Upturn AI SWOT
CervoMed Inc.
Company Overview
History and Background
CervoMed Inc. is a clinical stage company focused on developing innovative treatments for age-related cognitive decline and neurodegenerative diseases. While the exact founding date is unavailable in the prompt, they have reached Phase 3 clinical trials with their leading drug. A more detailed history is needed through reliable source information.
Core Business Areas
- Drug Development: CervoMed focuses on the development and commercialization of therapeutics for age-related cognitive decline and neurodegenerative diseases.
- Clinical Trials: The company is actively involved in conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
Specific details about CervoMed's leadership team and organizational structure are not available in the provided context. Further research is needed for an accurate representation.
Top Products and Market Share
Key Offerings
- Neuralstem (CRM-002): CervoMed's lead drug candidate currently in Phase 3 clinical trials for the treatment of age-related cognitive decline, specifically mild to moderate Alzheimer's disease. Market share data is currently unavailable. Competitors include pharmaceutical companies developing similar Alzheimer's treatments like Biogen (ADUHELM, LEQEMBI) and Eli Lilly (donanemab, if approved).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurodegenerative diseases is large and growing, driven by an aging global population. There's high demand for effective treatments for Alzheimer's disease and other cognitive impairments.
Positioning
CervoMed is a smaller player in a highly competitive field. Its competitive advantage, if any, depends on the efficacy and safety profile of their Neuralstem drug candidate, pending positive clinical trial results. Their ability to secure partnerships and funding will be important for long term success.
Total Addressable Market (TAM)
The global Alzheimer's disease market is estimated to be in the tens of billions of dollars annually and is expected to grow. CervoMed's positioning relative to this TAM depends on the success of its clinical trials and commercialization efforts. Even a small percentage of this market would be a significant achievement.
Upturn SWOT Analysis
Strengths
- Lead drug candidate in Phase 3 trials
- Focus on a significant unmet medical need (Alzheimer's)
- Experienced management team (assumed, needs validation through source)
Weaknesses
- Single primary drug candidate - risk of failure
- Limited financial resources compared to larger pharmaceutical companies
- High regulatory hurdles for drug approval
Opportunities
- Positive clinical trial results leading to FDA approval
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion into other neurodegenerative disease indications
Threats
- Failure of Phase 3 clinical trials
- Competition from existing and emerging treatments
- Regulatory setbacks
- Generic Erosion
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ABBV
Competitive Landscape
CervoMed operates in a competitive market dominated by larger pharmaceutical companies. Its success hinges on the unique benefits of its Neuralstem drug candidate versus existing and emerging treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, as CervoMed is primarily in the development stage.
Future Projections: Future growth depends heavily on the success of Neuralstem. Analyst estimates are unavailable without deeper research into the company's coverage.
Recent Initiatives: Recent initiative is moving Neuralstem to Phase 3 trials. Any partnerships or fundraising activities would also be relevant.
Summary
CervoMed is a high-risk, high-reward company focused on developing a treatment for Alzheimer's disease. Its Phase 3 clinical trials are the key to its future. While the company faces significant competition and financial constraints, successful trial results could lead to substantial returns. Investors should carefully consider the inherent risks before investing. Access to financial data is needed for further analysis
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings (where available). Information is also based on common knowledge and understanding of the pharmaceutical industry.
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share is an approximation.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CervoMed Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2016-01-04 | Co-Founder, CEO, President & Director Dr. John J. Alam M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.cervomed.com |
Full time employees 15 | Website https://www.cervomed.com | ||
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.